Compare Novavax Inc (NVAX) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while ZIM Integrated Shipping Services Ltd trades at $29.99 (market cap $3.65B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 2× Novavax Inc's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| NVAX | ZIM | |
|---|---|---|
Market Cap | $1.82B | $3.65B |
Volume | 6,198,505 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $12.56 | $30.51 |
52-Week Low | $6.22 | $12.44 |
Typical Hold Time | 59 Days | 27 Days |
Enterprise Value | $1.39B | $7.32B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
ZIM trades at $29.99, near its 52-week high of $30.96, reflecting strong momentum. The stock shows a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.53 versus a forecasted loss, driven by higher freight rates and volumes. Revenue for 2026 is projected at $6.4B with a net income margin of 2.15%. The company faces a pivotal moment with Hapag-Lloyd's acquisition offer under Israeli government review.
The outlook is mixed: operational improvements and record transpacific rates offer upside, but merger uncertainty caps near-term gains. Risks include deal rejection, competitive pressures, and volatile shipping rates. Analysts are cautious, with 67% hold ratings, signaling wait-and-see sentiment amid the acquisition saga.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
